Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
2012 2
2013 2
2015 1
2018 1
2020 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.
Salazar Y, Zheng X, Brunn D, Raifer H, Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, Dumoutier L, Renauld JC, Waisman A, Schmall A, Tufman A, Fink L, Brüne B, Bopp T, Grimminger F, Seeger W, Pullamsetti SS, Huber M, Savai R. Salazar Y, et al. Among authors: schmall a. J Clin Invest. 2020 Jul 1;130(7):3560-3575. doi: 10.1172/JCI124037. J Clin Invest. 2020. PMID: 32229721 Free PMC article.
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study.
Rahbar K, Essler M, Pabst KM, Eiber M, Fougère C, Prasad V, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Fendler WP, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. Among authors: schmall a. J Nucl Med. 2023 Apr;64(4):574-578. doi: 10.2967/jnumed.122.264456. Epub 2022 Oct 27. J Nucl Med. 2023. PMID: 36302656 Free PMC article.
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).
Rahbar K, Essler M, Eiber M, la Fougère C, Prasad V, Fendler WP, Rassek P, Hasa E, Dittmann H, Bundschuh RA, Pabst KM, Kurtinecz M, Schmall A, Verholen F, Sartor O. Rahbar K, et al. Among authors: schmall a. J Nucl Med. 2023 Dec 1;64(12):1925-1931. doi: 10.2967/jnumed.123.266125. J Nucl Med. 2023. PMID: 37827838 Free PMC article.
Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.
O'Sullivan JM, McKay RR, Rahbar K, Fizazi K, George DJ, Tombal B, Schmall A, Sandström P, Verholen F, Shore N. O'Sullivan JM, et al. Among authors: schmall a. Front Med (Lausanne). 2022 Dec 22;9:fmed-09-1070392. doi: 10.3389/fmed.2022.1070392. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619649 Free PMC article. Review.
Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation.
Hattar K, Savai R, Subtil FS, Wilhelm J, Schmall A, Lang DS, Goldmann T, Eul B, Dahlem G, Fink L, Schermuly RT, Banat GA, Sibelius U, Grimminger F, Vollmer E, Seeger W, Grandel U. Hattar K, et al. Among authors: schmall a. Cancer Immunol Immunother. 2013 Feb;62(2):309-20. doi: 10.1007/s00262-012-1341-2. Epub 2012 Aug 26. Cancer Immunol Immunother. 2013. PMID: 22923191 Free PMC article.